Gruppo Italiano Malattie EMatologiche dell'Adulto: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials
The registry lists 24 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor. 4 are open to participants now and 3 have results posted.
Phase 1 1Phase 2 15Phase 3 1No phase 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic LeukemiaNot yet recruitingNCT07623655
- Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-worldNot yet recruitingNCT07356960
- Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INORecruitingNCT06025682
- Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALLRecruitingNCT04582487Not applicable
- Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) AdultsCompletedNCT01462253Phase 2Results posted
- Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic LeukemiaCompletedNCT00458848Phase 2Results posted
- Treatment of Adult Ph+ LAL With BMS-354825CompletedNCT00391989Phase 2Results posted
- Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia PatientsActive, not recruitingNCT05306301Phase 2
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
- Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological RelapseActive, not recruitingNCT04475731Phase 2
- Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT03668392Phase 2
- Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT03610438Phase 2
- Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaCompletedNCT03367299Phase 2
- Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus unknownNCT03318770
- D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02744768Phase 2
- Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
- Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT02185781Phase 1
- MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted MethotrexateCompletedNCT02067143Phase 2
- De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) PatientsStatus unknownNCT01361438Phase 2
- Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic LeukemiaCompletedNCT01156883Not applicable
- Adult ALL Treatment at DiagnosisCompletedNCT00537550Not applicable
- "Geriatric Assessment Adapted" Therapy for Ph- ALL Elderly PatientsCompletedNCT00475280Phase 2
- GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.Status unknownNCT00439920Phase 2
- STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic LeukemiaCompletedNCT00376467Phase 2